Biosimilar substitution on the table in Australia
This article was originally published in Scrip
Australia's Pharmaceutical Benefits Advisory Committee (PBAC) is considering whether biosimilars could be marked as equivalent to their reference drug in the Schedule of Pharmaceutical Benefits – a move that would allow biosimilar substitution at the pharmacy level.
You may also be interested in...
Progress is being made towards the implementation of the EU’s new patent system, but the UK’s insistence on severing all ties with the European Court could spell the end for its participation.
The recruitment process for the new executive director of the European Medicines Agency seems to be running to schedule.
Russia’s new drug traceability system won’t now be implemented until July, but companies that are ready and able are being encouraged to put the system through its paces in order to flush out any glitches.